# Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

> **NCT07228832** · PHASE3 · RECRUITING · sponsor: **Summit Therapeutics** · enrollment: 600 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (CRC)

## Interventions

- **DRUG:** Drug: Ivonescimab Injection
- **DRUG:** Drug: Bevacizumab Injection

## Key facts

- **NCT ID:** NCT07228832
- **Lead sponsor:** Summit Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2028-05-31
- **Final completion:** 2029-11-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228832, "Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07228832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*